68Ga-P16-093 PET/CT Imaging in Glioma Patients

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including glioma. This makes it a potentially imaging target for the detection and grading of gliomas. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with MRI in the same group of glioma patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• glioma patients highly suggested by MRI or histologically confirmed;

• 68Ga-P16-093 PET/CT and MRI within two weeks;

• signed written consent.

Exclusion Criteria:

• known allergy against PSMA;

• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.